Cat. #154096
MEF2BD83V Mouse
Cat. #: 154096
Sub-type: Mouse
Availability: 6-8 weeks
Disease: B-Cell Lymphoma
Model: Knock-In
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Riccardo Dalla-Favera
Institute: The Trustees of Columbia University in the City of New York
Tool Details
*FOR RESEARCH USE ONLY
- Tool name: MEF2BD83V Mouse
- Alternate name: Myocyte Enhancer Factor 2B, Serum Response Factor-Like Protein 2, RSRFR2, XMEF2
- Tool sub type: Mouse
- Disease: B-Cell Lymphoma
- Model: Knock-In
- Conditional description: Conditional Knockin mice that express mutant MEF2BD38V upon recombination by Cre-recombinase
- Description: Diffuse large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) are the two most common forms of mature B cell lymphoid neoplams, accounting for over 50% of all diagnoses. Mutant MEF2B (MEF2BD83V) is the most common lymphoma associated oncogene. MEF2BD83V expression in mice leads to GC enlargement and lymphoma development, a phenotype that becomes fully penetrant in combination with BCL2 de-regulation, an event associated with human MEF2B mutations. Expression of the mutant MEF2BD38V allele was induced in germinal centre- derived B cells by crossing with C
- Genetic background: The conditional Mef2bstopD83V allele was generated by introducing a single nucleotide change by site directed mutagenesis leading to the D83V amino-acid change in exon 3. The neomycin-resistance marker followed by a triple-polyA, flanked by two loxP sites was introduced upstream the exon 3 carrying the D83V mutation. Correctly targeted mouse ES cells were injected into blastocysts derived from C57BL/6 mice to generate chimeras.
- Zygosity: Homozygous
- Strain: C57BL/6
- Production details: The conditional Mef2bstopD83V allele was generated by introducing a single nucleotide change by site directed mutagenesis leading to the D83V amino-acid change in exon 3. The neomycin-resistance marker followed by a triple-polyA, flanked by two loxP sites was introduced upstream the exon 3 carrying the D83V mutation. Correctly targeted mouse ES cells were injected into blastocysts derived from C57BL/6 mice to generate chimeras.
Handling
- Shipping conditions: Embryo/Spermatoza- Dry Ice
Target Details
- Target: MEF2B
References
- Brescia et al. 2018. Cancer Cell. 34(3):453-465.e9. PMID: 30205047.
- MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis.
